Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

Progress of Phase I Programme With Oral Iclaprim "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of

First Modules due Before Year-end 2007

REINACH, Switzerland, December 12 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the enrolment and dosing of the first patients in the Phase II clinical study with intravenous iclaprim in the treatment of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) / healthcare-associated pneumonia (HCAP).

In addition, Arpida announced results of a Phase I study with oral iclaprim. The primary aim of the study was to assess the safety and tolerability of single ascending doses of an oral capsule formulation of iclaprim in healthy volunteers.

Moreover, Arpida today announced that the first modules of the New Drug Application (NDA) for intravenous iclaprim in its first indication, cSSSI, are ready and will be filed before year-end 2007. The filing of the NDA package is expected to be completed by the end of February 2008.

First patients enrolled in Phase II trial with intravenous iclaprim in HAP/VAP/HCAP

Patient recruitment has started and several additional clinical centres are expected to start recruiting within the next few weeks. The trial remains on track for completion in 2008.

HAP/VAP/HCAP as a potential second indication could substantially enhance iclaprim's prospects as a potent novel therapy against multi-drug resistant bacteria. In the area of pneumonia, the need for new drugs addressing MRSA-infections is particularly pressing.

The Phase II trial is designed as a multi-centre, randomised, double-blind, comparative study. The efficacy and safety of two different dosing regimens of iclaprim will be compared to the current standard of care vancomycin. More than 130 patients will be enrolled. Patients will be treated for 7-14 days and a Test-of-Cure (TOC) visit will be performed 7-14
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  WIRB-Copernicus Group (WCG), the ... services for clinical research, announced today that its ... been reaccredited by the Association for the Accreditation ... to improve safeguards for clinical research participants. ... Deieso , Ph.D., commented, "It is of utmost ...
(Date:9/22/2014)... Mass. , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic ... of Robert Bazemore as Chief Operating ... , President and Chief Executive Officer, Robert will ... company,s lead program, sebelipase alfa for LAL Deficiency, ...
(Date:9/21/2014)... to produce ultra-thin "diamond nanothreads" that promise extraordinary properties, ... strongest nanotubes and polymers. A paper describing this discovery ... a professor of chemistry at Penn State University, will ... the journal Nature Materials . , "From a ... the threads we formed have a structure that has ...
(Date:9/20/2014)... HealthTronics, Inc. , a leading ... and services, has signed a distribution agreement through ... for its high precision laser technology. ... mobile, surgical technology—offering more choices for healthcare providers ... will make available Clinicon’s FDA-cleared SureLase™ CO2 Laser ...
Breaking Biology Technology:Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... The Albert and Mary Lasker Foundation, which for 66 ... the winners of the 2011 Lasker Awards : Franz ... basic medical research, Tu Youyou for clinical research and ... for public service. The Lasker Awards – considered among the most ...
... 2011 Mass High Tech has selected ... recipient of its 2011 All-Stars Award, one that recognizes ... economy.   Camacho will be recognized for ... the life sciences sector.  As a patent attorney, she ...
... low-intensity, pulsed ultrasound can be used to noninvasively ... rapid-response medical devices. The team that made that ... professor with the Virginia Tech Carilion Research Institute, ... approach, which may one day lead to first-line ...
Cached Biology Technology:2011 Lasker Awards Honor Medical Research Pioneers 22011 Lasker Awards Honor Medical Research Pioneers 32011 Lasker Awards Honor Medical Research Pioneers 42011 Lasker Awards Honor Medical Research Pioneers 52011 Lasker Awards Honor Medical Research Pioneers 62011 Lasker Awards Honor Medical Research Pioneers 7Greenberg Traurig Shareholder Jennifer A. Camacho Selected to Receive Mass High Tech's 2011 All-Stars Award 2Neuroscientists produce guide for ultrasound use to treat brain disorders in clinical emergencies 2Neuroscientists produce guide for ultrasound use to treat brain disorders in clinical emergencies 3
(Date:9/22/2014)... If you,re overweight, you may be at greater ... cardiovascular disease and cancer, according to a new ... that psychological stress can trigger biological responses similar ... inflammation. While normal inflammation is an important part ... contribute to chronic and life-threatening diseases. , ...
(Date:9/22/2014)... Conn. , Sept. 22, 2014 NXT-ID, ... company focused on the growing mobile commerce market, issues ... NASDAQ and the recent funding. ... completed an essential round of funding and joined the ... well as expand its other biometric and authentication products ...
(Date:9/21/2014)... events focussed on ways to save and improve the ... funded by the Government of Canada, today announced $2.4 ... this challenge. , The novel approaches include: , ... garment factories to express, pasteurize and store breast milk ... child illnesses, and lowering baby formula expense , ...
Breaking Biology News(10 mins):Obesity and stress pack a double hit for health 2NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 2Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 3Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 4Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 5Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 6Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 7Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 8Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 9Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 10Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 11Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 12Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 13Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 14Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 15
... -- Jade Holding Group, LLC dba Strax Rejuvenation, one ... wellness centers, has just announced that it is now ... and women who are interested in getting a hair ... to help. (Photo: http://photos.prnewswire.com/prnh/20130830/MN72022 ) ...
... York have discovered that very small chemical changes to dietary ... are tested for their impact on the human immune system., ... small molecules an average leaf for example, produces around ... and some are already known to have medicinal properties with ...
... receive $1.3 million over the next five years from ... Diseases (NIDDK) for research that will help better understand ... of novel treatments to reverse the disease. The ... suffer from type 2 diabetes--a number expected to double ...
Cached Biology News:Hair Transplant Offer and No-Cost Consultation are Now Available at Strax Rejuvenation 2Hair Transplant Offer and No-Cost Consultation are Now Available at Strax Rejuvenation 3Little changes -- large effects 2Type 2 diabetes study to examine role amylin plays in disease 2
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Tube-O-DIALYZER Floats, small....
Nestin, Human...
Biology Products: